Country: Canada
Language: English
Source: Health Canada
COAGULATION FACTOR IX (RECOMBINANT)
PFIZER CANADA ULC
B02BD04
COAGULATION FACTOR IX
3000UNIT
POWDER FOR SOLUTION
COAGULATION FACTOR IX (RECOMBINANT) 3000UNIT
INTRAVENOUS
15G/50G
Schedule D
HEMOSTATICS
Active ingredient group (AIG) number: 0152202005; AHFS:
APPROVED
2012-09-05
_ _ _BeneFIX_ _®_ _ (coagulation factor IX) Product Monograph _ _Page 1 of 30 _ PRODUCT MONOGRAPH BENEFIX ® COAGULATION FACTOR IX (RECOMBINANT) INN= NONACOG ALFA BENEFIX COAGULATION FACTOR IX (RECOMBINANT), IS PREPARED IN SIX LYOPHILIZED POWDER DOSAGE FORMS NOMINALLY CONTAINING 250, 500, 1000, 1500, 2000 AND 3000 IU PER VIAL. THE RECONSTITUTED PRODUCT CONTAINS APPROXIMATELY: 50, 100, 200, 300, 400 AND 600 IU/ML, RESPECTIVELY. WORLD HEALTH ORGANIZATION (WHO) INTERNATIONAL STANDARD FOR FACTOR IX CONCENTRATE ANTIHEMORRHAGIC BLOOD COAGULATION FACTOR IX ® T.M. GENETICS INSTITUTE LLC PFIZER CANADA INC., LICENSEE 17,300 TRANS-CANADA HIGHWAY KIRKLAND, QUEBEC H9J 2M5 SUBMISSION CONTROL NO: 200822 DATE OF APPROVAL: JULY 21, 2017 © PFIZER CANADA INC. _ _ _BeneFIX_ _®_ _ (coagulation factor IX) Product Monograph _ _Page 2 of 30 _ _ _ _BeneFIX_ _®_ _ (coagulation factor IX) Product Monograph _ _Page 3 of 30 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 4 SUMMARY PRODUCT INFORMATION ............................................................................. 4 INDICATIONS AND CLINICAL USE ................................................................................... 4 CONTRAINDICATIONS.......................................................................................................... 5 WARNINGS AND PRECAUTIONS ........................................................................................ 5 ADVERSE REACTIONS .......................................................................................................... 8 DRUG INTERACTIONS ........................................................................................................ 10 DOSAGE AND ADMINISTRATION .................................................................................... 10 OVERDOSAGE ........................................................................................................................ 14 ACTION AND CLINICAL PHARMACOLOGY........... Read the complete document